Grand Pharma acquires Shenming Medical for RMB22.6M

China Grand Pharmaceutical and Healthcare Holdings (GP HK) acquired 100% of Jiangsu Shenming Medical Technology for RMB22.6 million, obtaining rights to a thermosensitive embolic agent for liver cancer treatment.

“the Group will invest RMB22.6 million and obtain 100% equity interest of Shenming Medical”grandpharm.com

• 1 source
• grandpharm.comGP (HK) Acquires Shenming Medical Technology Co., Ltd. Obtains All Rights of an Innovative Thermosensitive Embolic Agent for the Treatment of Liver Cancer. Further Expands the Tumor Intervention Treatment Product Pipeline - Company - News Center - Grand Pharma GroupMay 26, 2021

Summarized from public sources; check the original articles before acting on it.